PDCD1 and diffuse large B-cell lymphoma: Several biological factors, in addition to M2-TAM and PD-1+ TILs, have been recommended as clinical predictors of DLBCL; these prognostic biomarkers are detected by gene expression profiling [13] and immunohistochemistry analysis [14, 15].